Independent role of Alzheimer's disease genetics and C-reactive protein on cognitive ability in aging

[1]  M. Jarvelin,et al.  Genetic analysis of over half a million people characterises C-reactive protein loci , 2022, Nature Communications.

[2]  Á. Pascual-Leone,et al.  Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer’s disease in healthy samples across the lifespan , 2021, Brain, Behavior, and Immunity.

[3]  K. Blennow,et al.  The probabilistic model of Alzheimer disease: the amyloid hypothesis revised , 2021, Nature Reviews Neuroscience.

[4]  C. Masters,et al.  Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems , 2021, Cellular and Molecular Life Sciences.

[5]  M. Heneka,et al.  Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus , 2021, Nature Reviews Neurology.

[6]  D. Monti,et al.  Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? , 2021, Ageing Research Reviews.

[7]  L. Nyberg,et al.  Sex-specific effects of polygenic risk for schizophrenia on lifespan cognitive functioning in healthy individuals , 2021, bioRxiv.

[8]  Danny J. Smith,et al.  The association between C-reactive protein, mood disorder, and cognitive function in UK Biobank , 2021, European Psychiatry.

[9]  K. Blennow,et al.  A Non-APOE Polygenic Risk Score for Alzheimer’s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds , 2021, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  O. Hansson,et al.  Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease , 2021, Scientific Reports.

[11]  B. de Strooper,et al.  Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores , 2021, Nature Communications.

[12]  K. Blennow,et al.  Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE ɛ4 negatives , 2021, Alzheimer's & dementia.

[13]  J. Manly,et al.  C-reactive protein and risk of cognitive decline: The REGARDS study , 2020, PloS one.

[14]  L. Tan,et al.  Inflammatory markers in Alzheimer's disease and mild cognitive impairment: A meta‐analysis and systematic review of 170 studies , 2020 .

[15]  D. Harold,et al.  The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[16]  C. Reitz,et al.  Late-onset vs nonmendelian early-onset Alzheimer disease , 2020, Neurology: Genetics.

[17]  K. Kauppi,et al.  Effects of polygenic risk for Alzheimer’s disease on rate of cognitive decline in normal aging , 2020, Translational Psychiatry.

[18]  I. Kullo,et al.  Sex-specific associations of inflammation markers with cognitive decline , 2020, Experimental Gerontology.

[19]  A. Fagan,et al.  APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline , 2020, Nature.

[20]  M. Hill,et al.  The multiplex model of the genetics of Alzheimer’s disease , 2020, Nature Neuroscience.

[21]  Ian J Deary,et al.  Reliability and validity of the UK Biobank cognitive tests , 2019, PloS one.

[22]  Emilie T. Reas,et al.  Identification of genetic heterogeneity of Alzheimer's disease across age , 2019, Neurobiology of Aging.

[23]  Joanna M. Biernacka,et al.  A principal component approach to improve association testing with polygenic risk scores , 2019, bioRxiv.

[24]  C. Stough,et al.  A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly , 2019, Front. Aging Neurosci..

[25]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[26]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[27]  Thao T. T. Nguyen,et al.  A biologically-informed polygenic score identifies endophenotypes and clinical conditions associated with the insulin receptor function on specific brain regions , 2019, EBioMedicine.

[28]  L. Tan,et al.  Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[30]  M. Laakso,et al.  Decreased plasma C‐reactive protein levels in APOE ε4 allele carriers , 2018, Annals of clinical and translational neurology.

[31]  C. Franceschi,et al.  Inflammaging: a new immune–metabolic viewpoint for age-related diseases , 2018, Nature Reviews Endocrinology.

[32]  Stuart J. Ritchie,et al.  Polygenic predictors of age-related decline in cognitive ability , 2018, bioRxiv.

[33]  Y. Luan,et al.  The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases , 2018, Front. Immunol..

[34]  Wuxiang Xie,et al.  High-sensitivity C-reactive protein and cognitive decline: the English Longitudinal Study of Ageing , 2017, Psychological Medicine.

[35]  Sterling C. Johnson,et al.  Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[36]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[37]  Jonathan J. Evans,et al.  Cognitive Test Scores in UK Biobank: Data Reduction in 480,416 Participants and Longitudinal Stability in 20,346 Participants , 2016, PloS one.

[38]  R. Kuwano,et al.  Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST) , 2016, Dementia and Geriatric Cognitive Disorders Extra.

[39]  Stuart J. Ritchie,et al.  Shared genetic aetiology between cognitive functions and physical and mental health in UK Biobank (N=112 151) and 24 GWAS consortia , 2015, Molecular Psychiatry.

[40]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[41]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[42]  I. Deary,et al.  Polygenic risk for Alzheimer's disease is not associated with cognitive ability or cognitive aging in non-demented older people. , 2014, Journal of Alzheimer's disease : JAD.

[43]  E. Crimmins,et al.  Sex differences in the association between muscle quality, inflammatory markers, and cognitive decline , 2011, The journal of nutrition, health & aging.

[44]  N. Sattar,et al.  C-Reactive Protein and Genetic Variants and Cognitive Decline in Old Age: The PROSPER Study , 2011, PloS one.

[45]  S. Waring,et al.  Decreased C-Reactive Protein Levels in Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.

[46]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[47]  R. Honea,et al.  Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. , 2009, Journal of Alzheimer's disease : JAD.

[48]  Jun Tan,et al.  Inflammaging as a prodrome to Alzheimer's disease , 2008, Journal of Neuroinflammation.

[49]  Peter M Visscher,et al.  Prediction of individual genetic risk to disease from genome-wide association studies. , 2007, Genome research.

[50]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[51]  Tatiana Tatusova,et al.  NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins , 2004, Nucleic Acids Res..

[52]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[53]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[54]  R. Schmidt,et al.  Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study , 2002, Annals of neurology.